Marta Benavent1, Javier Sastre2, Ignacio García Escobar3, Angel Segura4, Jaume Capdevila5, Alberto Carmona6, Isabel Sevilla7, Teresa Alonso8, Guillermo Crespo9, Lourdes García10, Neus Canal11, Guillermo de la Cruz12, Javier Gallego13. 1. Virgen Del Rocío University Hospital, Biomedicine Institut Biomedicina of Sevilla (IBIS), Av. Manuel Siurot, S/n, 41013, Sevilla, Spain. martabenaventv@gmail.com. 2. San Carlos Clinic Hospital, San Carlos Hospital Research Institute (IdISSC), Madrid, Spain. 3. San Pedro De Alcántara Hospital, Cáceres, Spain. 4. Politécnico La Fe University Hospital, Valencia, Spain. 5. Teknon Oncologic Institut (IOT), Teknon Medical Center, Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain. 6. Morales Meseguer General University Hospital, Murcia, Spain. 7. Clinical and Translational Research in Cancer, Biomedical Research Institut of Malaga (IBIMA), Regional University Hospital and Virgen de la Victoria University Hospital of Málaga, Málaga, Spain. 8. Ramón y Cajal Hospital, Madrid, Spain. 9. Burgos University Hospital, Burgos, Spain. 10. Segovia General Hospital, Segovia, Spain. 11. IQVIA Information S.A., Barcelona, Spain. 12. Ipsen Pharma S.A., Barcelona, Spain. 13. Hospital General Universitario de Elche, Elche, Alicante, Spain.
Abstract
BACKGROUND AND OBJECTIVE: Patient-reported outcome measures can provide clinicians with valuable information to improve doctor-patient communication and inform clinical decision-making. The aim of this study was to evaluate the physician-perceived utility of the QLQ-GINET21 in routine clinical practice in patients with gastrointestinal neuroendocrine tumours (GI-NETs). Secondary aims were to explore the patient, clinician, and/or centre-related variables potentially associated with perceived clinical utility. METHODS: Non-interventional, cross-sectional, multicentre study conducted at 34 hospitals in Spain and Portugal (NCT02853422). Patients diagnosed with GI-NETs completed two health-related quality of life (HRQoL) questionnaires (QLQ-C30, QLQ-GINET21) during a single routine visit. Physicians completed a 14-item ad hoc survey to rate the clinical utility of QLQ-GINET21 on three dimensions: 1)therapeutic and clinical decision-making, 2)doctor-patient communication, 3)questionnaire characteristics. RESULTS: A total of 199 patients at 34 centres were enrolled by 36 participating clinicians. The highest rated dimension on the QLQ-GINET21 was questionnaire characteristics (86.9% of responses indicating "high utility"), followed by doctor-patient communication (74.4%), and therapeutic and clinical decision-making (65.8%). One physician-related variable (GI-NET patient volume > 30 patients/year) was associated with high clinical utility and two variables (older age/less experience treating GI-NETs) with low clinical utility. CONCLUSIONS: Clinician-perceived clinical utility of QLQ-GINET21 is high. Clinicians valued the instruments' capacity to provide a better understanding of patient perspectives and to identify the factors that had the largest influence on patient HRQoL.
BACKGROUND AND OBJECTIVE:Patient-reported outcome measures can provide clinicians with valuable information to improve doctor-patient communication and inform clinical decision-making. The aim of this study was to evaluate the physician-perceived utility of the QLQ-GINET21 in routine clinical practice in patients with gastrointestinal neuroendocrine tumours (GI-NETs). Secondary aims were to explore the patient, clinician, and/or centre-related variables potentially associated with perceived clinical utility. METHODS: Non-interventional, cross-sectional, multicentre study conducted at 34 hospitals in Spain and Portugal (NCT02853422). Patients diagnosed with GI-NETs completed two health-related quality of life (HRQoL) questionnaires (QLQ-C30, QLQ-GINET21) during a single routine visit. Physicians completed a 14-item ad hoc survey to rate the clinical utility of QLQ-GINET21 on three dimensions: 1)therapeutic and clinical decision-making, 2)doctor-patient communication, 3)questionnaire characteristics. RESULTS: A total of 199 patients at 34 centres were enrolled by 36 participating clinicians. The highest rated dimension on the QLQ-GINET21 was questionnaire characteristics (86.9% of responses indicating "high utility"), followed by doctor-patient communication (74.4%), and therapeutic and clinical decision-making (65.8%). One physician-related variable (GI-NET patient volume > 30 patients/year) was associated with high clinical utility and two variables (older age/less experience treating GI-NETs) with low clinical utility. CONCLUSIONS: Clinician-perceived clinical utility of QLQ-GINET21 is high. Clinicians valued the instruments' capacity to provide a better understanding of patient perspectives and to identify the factors that had the largest influence on patient HRQoL.
Authors: A H G Davies; G Larsson; J Ardill; E Friend; L Jones; M Falconi; R Bettini; M Koller; O Sezer; C Fleissner; B Taal; J M Blazeby; J K Ramage Journal: Eur J Cancer Date: 2006-01-18 Impact factor: 9.162
Authors: Donna L Berry; Brent A Blumenstein; Barbara Halpenny; Seth Wolpin; Jesse R Fann; Mary Austin-Seymour; Nigel Bush; Bryant T Karras; William B Lober; Ruth McCorkle Journal: J Clin Oncol Date: 2011-01-31 Impact factor: 44.544
Authors: M Albertelli; E Nazzari; S Sciallero; F Grillo; S Morbelli; F De Cian; G Cittadini; E Ambrosetti; A Ciarmiello; D Ferone Journal: J Endocrinol Invest Date: 2017-05-26 Impact factor: 4.256
Authors: Simron Singh; Sylvia L Asa; Chris Dey; Hagen Kennecke; David Laidley; Calvin Law; Timothy Asmis; David Chan; Shereen Ezzat; Rachel Goodwin; Ozgur Mete; Janice Pasieka; Juan Rivera; Ralph Wong; Eva Segelov; Daniel Rayson Journal: Cancer Treat Rev Date: 2016-05-17 Impact factor: 12.111
Authors: Ethan Basch; Allison M Deal; Mark G Kris; Howard I Scher; Clifford A Hudis; Paul Sabbatini; Lauren Rogak; Antonia V Bennett; Amylou C Dueck; Thomas M Atkinson; Joanne F Chou; Dorothy Dulko; Laura Sit; Allison Barz; Paul Novotny; Michael Fruscione; Jeff A Sloan; Deborah Schrag Journal: J Clin Oncol Date: 2015-12-07 Impact factor: 44.544
Authors: Catherine Watson; Craig William Tallentire; John K Ramage; Rajaventhan Srirajaskanthan; Oscar R Leeuwenkamp; Donna Fountain Journal: World J Gastroenterol Date: 2020-07-07 Impact factor: 5.742